1
|
Samykutty A, Grizzle WE, Fouts BL, McNally MW, Chuong P, Thomas A, Chiba A, Otali D, Woloszynska A, Said N, Frederick PJ, Jasinski J, Liu J, McNally LR. Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 2018; 182:114-126. [PMID: 30118979 PMCID: PMC6289590 DOI: 10.1016/j.biomaterials.2018.08.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Revised: 07/30/2018] [Accepted: 08/01/2018] [Indexed: 12/12/2022]
Abstract
At the intersection of the newly emerging fields of optoacoustic imaging and theranostic nanomedicine, promising clinical progress can be made in dismal prognosis of ovarian cancer. An acidic pH targeted wormhole mesoporous silica nanoparticle (V7-RUBY) was developed to serve as a novel tumor specific theranostic nanoparticle detectable using multispectral optoacoustic tomographic (MSOT) imaging. We report the synthesis of a small, < 40 nm, biocompatible asymmetric wormhole pore mesoporous silica core particle that has both large loading capacity and favorable release kinetics combined with tumor-specific targeting and gatekeeping. V7-RUBY exploits the acidic tumor microenvironment for tumor-specific targeting and tumor-specific release. In vitro, treatment with V7-RUBY containing either paclitaxel or carboplatin resulted in increased cell death at pH 6.6 in comparison to drug alone (p < 0.0001). In orthotopic ovarian xenograft mouse models, V7-RUBY containing IR780 was specifically detected within the tumor 7X and 4X higher than the liver and >10X higher than in the kidney using both multispectral optoacoustic tomography (MSOT) imaging with secondary confirmation using near infrared fluorescence imaging (p < 0.0004). The V7-RUBY system carrying a cargo of either contrast agent or an anti-neoplastic drug has the potential to become a theranostic nanoparticle which can improve both diagnosis and treatment of ovarian cancer.
Collapse
Affiliation(s)
- Abhilash Samykutty
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - William E Grizzle
- Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
| | - Benjamin L Fouts
- Department of Chemistry, Earlham College, Indianapolis, IN, 27013, USA
| | - Molly W McNally
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Phillip Chuong
- Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Alexandra Thomas
- Department of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Akiko Chiba
- Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Dennis Otali
- Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
| | - Anna Woloszynska
- Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Neveen Said
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Peter J Frederick
- Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Jacek Jasinski
- Conn Center Materials Characterization, University of Louisville, Louisville, KY 40202, USA
| | - Jie Liu
- Department of Forest Materials, North Carolina State University, Raleigh, NC 27695, USA
| | - Lacey R McNally
- Department of Bioengineering, Wake Forest School of Medicine, Winston-Salem, North Carolina 27013, USA; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA.
| |
Collapse
|
2
|
Graim K, Liu TT, Achrol AS, Paull EO, Newton Y, Chang SD, Harsh GR, Cordero SP, Rubin DL, Stuart JM. Revealing cancer subtypes with higher-order correlations applied to imaging and omics data. BMC Med Genomics 2017; 10:20. [PMID: 28359308 PMCID: PMC5374737 DOI: 10.1186/s12920-017-0256-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Accepted: 03/15/2017] [Indexed: 12/14/2022] Open
Abstract
Background Patient stratification to identify subtypes with different disease manifestations, severity, and expected survival time is a critical task in cancer diagnosis and treatment. While stratification approaches using various biomarkers (including high-throughput gene expression measurements) for patient-to-patient comparisons have been successful in elucidating previously unseen subtypes, there remains an untapped potential of incorporating various genotypic and phenotypic data to discover novel or improved groupings. Methods Here, we present HOCUS, a unified analytical framework for patient stratification that uses a community detection technique to extract subtypes out of sparse patient measurements. HOCUS constructs a patient-to-patient network from similarities in the data and iteratively groups and reconstructs the network into higher order clusters. We investigate the merits of using higher-order correlations to cluster samples of cancer patients in terms of their associations with survival outcomes. Results In an initial test of the method, the approach identifies cancer subtypes in mutation data of glioblastoma, ovarian, breast, prostate, and bladder cancers. In several cases, HOCUS provides an improvement over using the molecular features directly to compare samples. Application of HOCUS to glioblastoma images reveals a size and location classification of tumors that improves over human expert-based stratification. Conclusions Subtypes based on higher order features can reveal comparable or distinct groupings. The distinct solutions can provide biologically- and treatment-relevant solutions that are just as significant as solutions based on the original data. Electronic supplementary material The online version of this article (doi:10.1186/s12920-017-0256-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Kiley Graim
- Biomedical Engineering, University of California, Santa Cruz, USA.,UC Santa Cruz Genomics Institute, University of California, Santa Cruz, USA
| | - Tiffany Ting Liu
- Stanford Center for Biomedical Informatics Research and Biomedical Informatics Training Program, Stanford University School of Medicine, Stanford, USA.,Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine, Stanford, USA
| | - Achal S Achrol
- Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine, Stanford, USA.,Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, USA.,Departments of Neurosurgery, Stanford University School of Medicine, Stanford, USA
| | - Evan O Paull
- Biomedical Engineering, University of California, Santa Cruz, USA.,UC Santa Cruz Genomics Institute, University of California, Santa Cruz, USA
| | - Yulia Newton
- Biomedical Engineering, University of California, Santa Cruz, USA.,UC Santa Cruz Genomics Institute, University of California, Santa Cruz, USA
| | - Steven D Chang
- Departments of Neurosurgery, Stanford University School of Medicine, Stanford, USA
| | - Griffith R Harsh
- Departments of Neurosurgery, Stanford University School of Medicine, Stanford, USA
| | - Sergio P Cordero
- Biomedical Engineering, University of California, Santa Cruz, USA.,UC Santa Cruz Genomics Institute, University of California, Santa Cruz, USA
| | - Daniel L Rubin
- Stanford Center for Biomedical Informatics Research and Biomedical Informatics Training Program, Stanford University School of Medicine, Stanford, USA.,Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine, Stanford, USA
| | - Joshua M Stuart
- Biomedical Engineering, University of California, Santa Cruz, USA. .,UC Santa Cruz Genomics Institute, University of California, Santa Cruz, USA.
| |
Collapse
|